Altogether, this study verified the mechanism by which the TRIM25/BRD7/YB1/Bcl-2 axis is involved in the malignant progression and PTX resistance of breast cancer, providing a novel insight into BC development and potential targets for improving the PTX therapeutic resistance. Here, YBX1 is linked to breast cancer.